SCHEMBL6174293

SCHEMBL6174293

CN(C)CCOc1cc(NS(=O)(=O)c2ccc(Oc3cccc(Cl)c3C#N)cc2)ccc1Cl

nearest known ligand 0.62

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.62
HSD11B1 P28845 1/20 0.52
CACNA1B Q00975 8/20 0.51
CACNA1H O95180 6/20 0.51
BCL2L1 Q07817 1/20 0.48
MCL1 Q07820 1/20 0.48
PLA2G7 Q13093 6/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6176770 0.91 MAPT (0.59) MAPTHSD11B1CACNA1BCACNA1HBCL2L1
SCHEMBL6176698 0.90 MAPT (0.57) MAPTHSD11B1CACNA1BCACNA1HPLA2G7
SCHEMBL6176415 0.90 MAPT (0.48) MAPTHSD11B1CACNA1BCACNA1HBCL2L1
SCHEMBL6176083 0.89 CACNA1B (0.57) CACNA1BCACNA1H
SCHEMBL6178070 0.89 CACNA1B (0.52) MAPTCACNA1BCACNA1HPLA2G7
SCHEMBL6180569 0.88 MAPT (0.58) MAPTHSD11B1CACNA1BCACNA1HBCL2L1
SCHEMBL6176466 0.88 MAPT (0.47) MAPTHSD11B1CACNA1BCACNA1HBCL2L1
SCHEMBL6176095 0.88 MAPT (0.58) MAPTHSD11B1CACNA1BCACNA1HBCL2L1
SCHEMBL6176764 0.88 MAPT (0.46) MAPTHSD11B1CACNA1BCACNA1HBCL2L1
SCHEMBL6179473 0.84 CACNA1B (0.54) CACNA1BCACNA1H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399137-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2005-12-14 EP claimed
US-6849635-B2 Sulfonamides SMITHKLINE BEECHAM CORPORATION (US) 2005-02-01 US claimed
US-20040152893-A1 Sulfonamides SMITHKLINE BEECHAM CORPORATION 2004-08-05 US claimed
EP-1399137-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-03-24 EP claimed
WO-2002089785-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO claimed
EP-1399137-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2005-12-14 EP disclosed
US-20050119296-A1 Substituted heteroaryl benzofuran acids WYETH (US) 2005-06-02 US disclosed
US-6849635-B2 Sulfonamides SMITHKLINE BEECHAM CORPORATION (US) 2005-02-01 US disclosed
US-20040152893-A1 Sulfonamides SMITHKLINE BEECHAM CORPORATION 2004-08-05 US disclosed
EP-1399137-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-03-24 EP disclosed
WO-2002089785-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119296-A1 Substituted heteroaryl benzofuran acids AADAC, CYP3A43, COXFA4L2 MAPT 3597/4885HSD11B1 1269/4885CACNA1B 3124/4885
US-20040152893-A1 Sulfonamides UTS2R, PRSS2, STS MAPT 2260/4885HSD11B1 3366/4885CACNA1B 3246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.